Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Connective Tissue Diseases Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

5 recruiting trials for Connective Tissue Diseases. Eligibility criteria explained in plain English.

TrialFinderData lists 5 Connective Tissue Diseases clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 3 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Medical University Innsbruck (1), Oslo University Hospital (1), GlaxoSmithKline (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Pulmonary function test (diagnostic_test, 1 trial), followed by Imaging, Blood sampling.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
5
Total Trials
5
Recruiting Now
1
Phase 3 Trials
5
Sponsors

Track Connective Tissue Diseases trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT04095351

Connective Tissue Diseases and Lung Manifestations

Despite a number of prospective studies already initiated in the past years, the current epidemiology and course of interstitial lung disease (ILD) and pulmonary hypertension (PH)...

Sponsor: Medical University InnsbruckEnrolling: 1201 location
RECRUITINGNCT06732674

Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases

The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology. It...

Sponsor: Oslo University HospitalEnrolling: 2181 location
RECRUITINGPhase 3NCT06716606

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD)...

This is an open label extension (OLE) study of an ongoing randomized controlled parent clinical studies 218224 (NCT05878717) and 221672 (NCT06572384) which aim to assess the...

Sponsor: GlaxoSmithKlineEnrolling: 51410 locations
RECRUITINGNCT07541638

Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases

Connective tissue diseases (CTDs) cover a broad range of systemic rheumatic disorders characterized by abnormal immune activation, chronic inflammatory response, and fibrosis of...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 2001 location
RECRUITINGNCT07283081

Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias

The investigators hypothesize that in patients with a new diagnosis of Pulmonary Interstitial Disease (PID), adding capillaroscopy to standard care increases the proportion of...

Sponsor: University Hospital, BordeauxEnrolling: 481 location

Frequently Asked Questions

There are currently 5 clinical trials for Connective Tissue Diseases, with 5 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Connective Tissue Diseases, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Connective Tissue Diseases, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.